The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery Signs Distribution Agreement with Haplogen

12 Feb 2014

Horizon will market and distribute haploid gene trap mutant collection to its global customer base

Cambridge, UK, 12 February 2014: Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a worldwide distribution agreement with Haplogen GmbH (Haplogen), with immediate effect. Under the terms of the agreement customers can now access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. This agreement represents the first time that Horizon will be distributing another company’s products, recognizing Horizon’s past success in penetrating the global model cell lines market.

Haploid cellular models offer a biologically relevant system for in vitro genetic analyses of molecular, cellular, and developmental events in various cell lineages. Haplogen’s Haploid Gene Trap Mutant Collection is the largest haploid cell line bank available, and comprises over 9,400 mutant clones, affecting over 3,700 human genes and an additional 1,600 inducible clones covering 1,100 genes. For-profit customers will be able to access the cell-line bank by signing an annual limited use label license, whilst academic customers will be able to access an unlimited term license and will receive a greater than 90% discount.

“Horizon’s mission is to give scientists access to high value products and services that address their research needs,” commented Dr Darrin Disley, CEO, Horizon. “The addition of the Haplogen cell line products to our offering supports our growth strategy and is highly complementary to our current product portfolio, including our X-MAN™ range of diploid isogenic cell lines. We anticipate announcing further partnerships in the future as we continue to broaden our product offering to meet the needs of our customers.”

Dr Georg Casari, CEO, Haplogen, said: “We are delighted that a company of Horizon’s reputation and commercial reach is recognizing the potential of our Haploid Gene Trap Mutant Collection. This marketing and distribution agreement will help make our products accessible to a much broader range of customers active in the translational genomics field.”